NeoGenomics results, outlook, call

 Fourth Quarter Revenue Increased 10% to $139 million;

Full Year Revenue Increased 5% to $510 million

2023 Financial Guidance

The Company also issued 2023 guidance(3) today (in millions).

	FY 2022		FY 2023 Guidance				YOY % Change from FY 2022
	Actual		Low		High		Low		High
Consolidated revenue	$510		$545		$555		7%		9%
Net loss	$(144)		$(116)		$(107)		19%		26%
Adjusted EBITDA	$(48)		$(27)		$(22)		44%		54%

(1) Clinical testing excludes requisitions, tests, revenue and costs of revenue for Pharma Services.

(2) The Company has provided adjusted financial information that has not been prepared in accordance with GAAP, including Adjusted EBITDA, Adjusted Gross Profit Margin, Adjusted Net Loss, and Adjusted Diluted EPS. Each of these measures is defined in the section of this report entitled "Use of Non-GAAP Financial Measures." See also the tables reconciling such measures to their closest GAAP equivalent.

(3) The Company reserves the right to adjust this guidance at any time based on the ongoing execution of its business plan. Current and prospective investors are encouraged to perform their own due diligence before buying or selling any of the Company's securities, and are reminded that the foregoing estimates should not be construed as a guarantee of future performance.

Conference Call

The Company has scheduled a webcast and conference call to discuss its fourth quarter and full year 2022 results on Thursday, February 23, 2023 at 8:30 AM EDT. Interested investors should dial (888) 506-0062 (domestic) and (973) 528-0011 (international) at least five minutes prior to the call. The participant access code provided for this call is 647216. A replay of the conference call will be available until 8:30 AM EDT on March 9, 2023, and can be accessed by dialing (877) 481-4010 (domestic) and (919) 882-2331 (international). The playback conference ID number is 47529. The webcast may be accessed under the Investor Relations section of our website at www.neogenomics.com. An archive of the webcast will be available until 8:30 AM EDT on February 23, 2024.

https://finance.yahoo.com/news/neogenomics-reports-fourth-quarter-full-120000351.html

Lantheus results, guidance, call

 

• Worldwide revenue of $263.2 million and $935.1 million for the fourth quarter and full year 2022, representing increases of 103.1% and 119.9% over the prior year periods, respectively
  

• GAAP net loss of $119.2 million and GAAP net income of $28.1 million for the fourth quarter and full year 2022, compared to GAAP net loss of $40.2 million and $71.3 million in the prior year period

• GAAP fully diluted net loss per share of $1.74 and GAAP fully diluted net income per share of $0.40 for the fourth quarter and full year 2022, compared to GAAP fully diluted net loss per share of $0.59 and $1.06 in the prior year period; adjusted fully diluted net income per share of $1.37 and $4.22 for the fourth quarter and full year 2022, compared to adjusted fully diluted net income per share of $0.25 and $0.49 in the prior year period

• Net cash provided by operating activities was $105.4 million and $281.8 million for the fourth quarter and full year 2022. Free cash flow of $100.6 million and $263.4 million for the fourth quarter and full year 2022, compared to free cash flow of $9.3 million and $41.8 million for the fourth quarter and full year 2021

• The Company provides first quarter and full year 2023 revenue and adjusted diluted earnings per share guidance

The Company updates its guidance for the first quarter and full year 2023 is as follows:

		Guidance Issued February 23, 2023
Q1 FY 2023 Revenue		$280 million - $285 million
Q1 FY 2023 Adjusted Fully Diluted EPS		$1.28 - $1.32
		Guidance Issued February 23, 2023
FY 2023 Revenue		$1.140 billion - $1.160 billion
FY 2023 Adjusted Fully Diluted EPS		$4.95 - $5.10

Conference Call and Webcast

As previously announced, the Company will host a conference call and webcast on Thursday, February 23, 2023, at 8:00 a.m. ET. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events.

A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least 30 days.

The conference call will include a discussion of non-GAAP financial measures. Reference is made to the most directly comparable GAAP financial measures, the reconciliation of the differences between the two financial measures, and the other information included in this press release, our Form 8-K filed with the SEC today, or otherwise available in the Investor Relations section of our website located at www.lantheus.com.

https://finance.yahoo.com/news/lantheus-reports-fourth-quarter-full-120000862.html

Pulmonx guidance, webcast

 Full Year 2023 Financial Guidance

Pulmonx expects revenue for the full year 2023 to be in the range of $63 million to $65 million.

The Company expects gross margin for the full year 2023 to fall within the range of 73% to 74%.

Pulmonx expects total operating expenses for the full year 2023 to fall within the range of $112 million to $114 million, inclusive of approximately $22 million of non-cash stock-based compensation.

Webcast and Conference Call Details
Pulmonx will host a conference call today, February 22, 2023, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its fourth quarter and full year 2022 financial results and to discuss its full year 2023 financial guidance. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at https://investors.pulmonx.com/. The webcast will be archived on the website following the completion of the call.

https://finance.yahoo.com/news/pulmonx-reports-fourth-quarter-full-210500916.html

Ransomware Attack On Food Giant Dole Temporarily Shuttered US Production

 Dole Food is one of the world's largest producers and distributors of fresh fruits and vegetables. An alarming report reveals the company temporarily shuttered all operations across North America after a cyberattack earlier this month. 

"Dole Food Company is in the midst of a Cyber Attack and have subsequently shut down our systems throughout North America," Emanuel Lazopoulos, senior vice president at Dole's Fresh Vegetables division, wrote in a memo to retailers on Feb. 10. The memo was obtained by CNN this week. 

Dole sent the memo to supermarkets after customers complained about its prepackaged salads, which include salad blends, salad kits, and ready-to-eat salads, being out of stock. 

"Our plants are shut down for the day and all our shipments are on hold.

"Please bear with us as we navigate our way and hopefully we will minimize this event," the internal memo continued.

William Goldfield, the spokesperson for Dole, confirmed the ransomware incident in a statement released on the company's website on Wednesday. 

Dole plc announced today that the company recently experienced a cybersecurity incident that has been identified as ransomware.

Upon learning of this incident, Dole moved quickly to contain the threat and engaged leading third-party cybersecurity experts, who have been working in partnership with Dole's internal teams to remediate the issue and secure systems.

The company has notified law enforcement about the incident and are cooperating with their investigation.

While continuing to investigate the scope of the incident, the impact to Dole operations has been limited.

What's not clear is how long the company had to shutter production. There was no word if the company paid a ransom to hackers. 

Add Dole to the growing list of incidents at US food plants. Some folks are convinced the nation's food processing plants are 'under attack' after a series of fires (read: here & here & here). The FBI warned food plants to be alert for ransomware attacks last year. 

https://www.zerohedge.com/technology/ransomware-attack-food-giant-dole-temporarily-shuttered-us-production

US May Release Intelligence Showing China Poised To Transfer Arms To Russia

 The Biden administration says it has proof that China is strongly considering supplying Russia with lethal aid amid the war in Ukraine and that it may release this intelligence to the public. 

"The Biden administration is considering releasing intelligence it believes shows that China is weighing whether to supply weapons to support Russia’s war in Ukraine, U.S. officials said," The Wall Street Journal reports.

The details continue: "The discussions on public disclosure come ahead of Friday’s United Nations Security Council meeting marking one year since Russia invaded Ukraine. It follows a number of closed-door appeals to China—coordinated among North Atlantic Treaty Organization allies—that culminated in a formal warning delivered over the weekend in Munich to Wang Yi, China’s senior foreign-policy official, by a number of Western officials, including Secretary of State Antony Blinken and British Foreign Secretary James Cleverly."

In follow-up, Blinken told CBS News in a weekend interview the US has been "concerned" over potential Chinese military aid to Moscow. "We've been concerned from day one about that possibility," he had told "Face the Nation".

As for the types of defense aid, he said somewhat ambiguously, "There's a whole gamut of things that — that fit in that category, everything from ammunition to the weapons themselves." 

While the sources who spoke to the Journal said it's their belief that no final decision has been made, they say that intelligence - which is also possessed by Western allies - shows there's been a shift in thinking.

"Beijing had previously been cautious to confine its support to financial assistance and oil purchases, the officials said, but that stance now appears to be shifting, according to the latest intelligence assessments," WSJ continues.

A source identified only as a senior Western official described that "Until now... there has been a certain amount of ambiguity about what practical help China might give Russia." But at this point US intelligence has picked up on evidence that it's "much less ambiguous."

But, the entirety of WSJ's reporting is itself ambiguous, given that we're told the Chinese are mulling action but haven't made a final decision, and that merely the US is aware of their thinking. In reality the statements from US officials serve as a warning to Beijing, aired in the pages of the Journal.

https://www.zerohedge.com/geopolitical/us-may-release-intelligence-showing-china-poised-transfer-arms-russia 

Republican Senators Push Back Against Accord Giving WHO Power Over US Pandemic Response

 by Kevin Stocklin via The Epoch Times (emphasis ours),

As member states of the World Health Organization (WHO) prepare to gather in Switzerland next week to negotiate final terms of an accord that will give the WHO centralized authority over U.S. policy in the case of a pandemic, Republican senators are pushing back with an effort to reinforce congressional power to authorize treaties.

The draft accord, which would be “legally binding” on all 194 member nations, gives the WHO the authority to declare pandemics and submits member countries to “the central role of the WHO as the directing and coordinating authority on international health work,” in areas like lockdowns, treatments, medical supply chains, surveillance, and “disinformation and false news,” once a pandemic is declared.

Seventeen U.S. senators, led by Ron Johnson (R-Wis.), introduced the “No WHO Pandemic Preparedness Treaty Without Senate Approval Act” on Feb 15, which states that the pandemic accord must be deemed a treaty, thus requiring the consent of a supermajority of the Senate, which is two-thirds, or 67 senators. The legislation comes as the WHO gears up to present what it calls the “zero draft” of the accord, negotiated with the help of U.S. Health and Human Services Secretary Xavier Becerra, to all member nations on Feb. 27 to agree final terms.

Other sponsors of the bill included Chuck Grassley (R-Iowa), Bill Hagerty (R-Tenn.), John Barrasso (R-Wyo.), Mike Lee (R-Utah), Marsha Blackburn (R-Tenn.), Rick Scott (R-Fla.), John Hoeven (R-N.D.), Marco Rubio (R-Fla.), Ted Cruz (R-Texas), Steve Daines (R-Mont.), Thom Tillis (R-N.C.), Tom Cotton (R-Ark.), Mike Braun (R-Ind.), Tommy Tuberville (R-Ala.), Roger Marshall (R-Kan.), and Katie Britt (R-Ala.).

“The WHO, along with our federal health agencies, failed miserably in their response to COVID-19,” Sen. Johnson stated. “This failure should not be rewarded with a new international treaty that would increase the WHO’s power at the expense of American sovereignty.”

But some doubt this bill, even if approved, will stop the WHO accord from going into effect once President Joe Biden signs it.

“With all due respect to the sponsoring senators, that will not do the trick,” Francis Boyle, professor of international law at Illinois University, told The Epoch Times. The reason, he said, is that the WHO accord is drafted specifically to circumvent the Senate-approval process, and Congress instead should immediately withhold its yearly contributions to the WHO and take the United States out of the organization.

Currently, the United States is the largest contributor to the WHO’s $6.72 billion budget, of which $1.25 billion is for “health emergencies.” The Bill and Melinda Gates Foundation is the second largest donor to the WHO, contributing 9 percent of its budget in 2021; China is the third.

Will Biden Need Senate Approval for WHO Accord?

It remains unclear if the Biden administration will need Senate approval for the WHO accord to go into effect. The accord itself states that it will become effective and legally binding on member states “provisionally,” as soon as it is signed and before any national legislatures approve it.

“The Biden administration can indicate that it is provisionally bringing this treaty into force upon the mere signature of the treaty,” Boyle said. “Hence, it will come into force here in the United States provisionally until the Senate decides whether or not it is going to give its advice and consent to the treaty. I personally know of no other U.S. treaty that provides for its provisional application pending the U.S. Senate giving its advice and consent to the treaty.”

https://www.zerohedge.com/political/republican-senators-push-back-against-accord-giving-who-power-over-us-pandemic-response

Regeneron: Priority review for macular edema therapy

BLA supported by two pivotal trials demonstrating non-inferior vision gains to EYLEA® (aflibercept) Injection, with vast majority of patients maintaining extended dosing regimens through 48 weeks

If approved, aflibercept 8 mg will be second ophthalmology medicine developed by Regeneron

https://finance.yahoo.com/news/aflibercept-8-mg-bla-treatment-120000822.html